This study identifies circulating interleukins—particularly IL-1RA, IL-6, IL-8, IL-10, and IL-17A—as promising blood-based biomarkers for the early detection of non-small cell lung cancer (NSCLC). Here, IL17A is linked to non-small cell lung carcinoma.